The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How to treat triple-class refractory MM?

Sep 15, 2020

During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the Multiple Myeloma Hub spoke to Shaji Kumar, Mayo Clinic, Rochester, US, about how to treat patients with triple-class refractory MM.

How to treat triple-class refractory MM?

Despite the introduction of several new classes of drugs in the MM setting, which have resulted in improved depth and duration of remission, the disease relapses in a proportion of patients. Increased understanding of the genetic evolution of MM cells might allow for effective disease control through treatment with combination regimens.

Here, Shaji Kumar outlines the different treatment approaches to triple-class refractory MM, including the newly available agents selinexor and belantamab mafodotin, as well as emerging therapies, including venetoclax, melflufen, and immunotherapy.